Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle  branch block patients. by Kosztin, Annamária et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CLINICAL RESEARCH
Longer right to left ventricular activation delay at
cardiac resynchronization therapy implantation is
associated with improved clinical outcome in left
bundle branch block patients
Annamaria Kosztin†, Valentina Kutyifa†, Vivien Klaudia Nagy, Laszlo Geller,
Endre Zima, Levente Molnar, Szabolcs Szilagyi, Emin Evren Ozcan,
Gabor Szeplaki‡, and Bela Merkely‡,*
Heart and Vascular Center, Semmelweis University, Varosmajor 68, Budapest H-1122, Hungary
Received 6 November 2014; accepted after revision 8 April 2015
Aims Data on longer right to left ventricular activation delay (RV-LVAD) predicting clinical outcome after cardiac resynchro-
nization therapy (CRT) by left bundle branch block (LBBB) are limited. We aimed to evaluate the impact of RV-LVAD on
N-terminal pro–B-type natriuretic peptide (NT-proBNP), ejection fraction (EF), and clinical outcome in patients
implanted with CRT, stratified by LBBB at baseline.
Methods
and results
Heart failure (HF) patients undergoing CRT implantation with EF ≤ 35% and QRS ≥ 120 ms were evaluated based on
their RV-LV AD at implantation. Baseline and 6-month clinical parameters, EF, and NT-proBNP values were assessed.
The primary endpoint was HF or death, the secondary endpoint was all-cause mortality. A total of 125 patients with
CRT were studied, 62% had LBBB. During the median follow-up of 2.2 years, 44 (35%) patients had HF/death, 36
(29%) patients died. Patients with RV-LV AD ≥ 86 ms (lower quartile) had significantly lower risk of HF/death [hazard
ratio (HR): 0.44; 95% confidence interval (95% CI): 0.23–0.82; P ¼ 0.001] and all-cause mortality (HR: 0.48; 95% CI:
0.23–1.00; P ¼ 0.05), compared with those with RV-LV AD, 86 ms. Patients with RV-LV AD ≥ 86 ms and LBBB
showed the greatest improvement in EF (28–36%; P, 0.001), NT-proBNP (2771–1216 ng/mL; P, 0.001), and they
had better HF-free survival (HR: 0.23, 95% CI: 0.11–0.49, P, 0.001) and overall survival (HR: 0.35, 95% CI: 0.16–
0.75; P ¼ 0.007). There was no difference in outcome by RV-LV AD in non-LBBB patients.
Conclusion Left bundle branch block patients with longer RV-LV activation delay at CRT implantation had greater improvement
in NT-proBNP, EF, and significantly better clinical outcome.
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Introduction
Cardiac resynchronization therapy (CRT) has been shown to
improve cardiac function, heart failure (HF) symptoms, and to
reduce hospitalization and all-cause mortality in patients with mild
to severe HF and a prolonged QRS.1– 3
Recent studies have suggested that patients with a left bundle
branch block (LBBB) ECG morphology derive a significant benefit
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from the implantation of CRT, while in patients with a non-LBBB
[right bundle branch block (RBBB), or intraventricular conduction
delay], the benefit is less if at all discernible.4,5
It has been proposed that optimal left ventricular (LV) lead place-
ment is an important determinant of response to CRT. The location
of the left and right ventricular leads affects clinical outcome, and the
incidence of ventricular tachyarrythmias.6 Furthermore, few smaller
studies have indicated that the electrical delay of the LV lead sensed
signal from the beginning of QRS duration (Q-LV), or the distance
between the electrical signals of the right to left ventricular activation
delay (RV-LV AD) predicted echocardiographic improvement and
clinical outcome.7– 9
However, there have been no studies conducted evaluating the
impact of RV-LV AD on N-terminal pro–B-type natriuretic peptide
(NT-proBNP) and prior studies on RV-LV AD did not assess the
differential effect in subgroups of LBBB and non-LBBB patients.
Therefore, the aim of this study was three-fold: (i) to evaluate the
impact of RV-LV activation delay on the biomarker of NT-proBNP,
(ii) on the echocardiographic improvement in ejection fraction
(EF), and (iii) on clinical outcome assessing HF or death, and all-cause
mortality in patients undergoing CRT implantation, by baseline LBBB
ECG pattern.
Methods
Patient population and follow-up
A prospective, observational, cohort study was designed including
patients with mild to severe chronic systolic HF (EF ≤ 35%) and a pro-
longed QRS (QRS ≥ 120 ms) undergoing successful CRT implantation
at the Heart and Vascular Center, Semmelweis University, Budapest,
Hungary. The study was conducted between September 2009 and
December 2010.
Inclusion criteria included CRT indication according to actual guide-
lines, with an EF under 35%, a prolonged baseline QRS interval (≥120 ms),
and symptoms of HF [New York Heart Association (NYHA) II– IV ambu-
latory functional class] on optimal medical treatment. Exclusion criteria
were patients with a known malignant disease, those with an inflamma-
tory disorder, or those with HF based on a genetic condition. We have
also excluded patients who were geographically unstable, or did not
provide consent to the study. The protocol was approved by the Institu-
tional Research Subjects Review Board. All patients provided written
informed consent before inclusion in the study.
Laboratory tests, echocardiographic examination, and physical assess-
ment were performed at baseline and 6 months after CRT implantation.
Patients were followed for a median of 2.2 years and clinic follow-up data,
and the National Hungarian Health Care Fund database was utilized to
assess whether the patients were alive at the end of the follow-up period.
ECG morphology criteria
Left bundle branch block was defined on 12-lead ECGs that were per-
formed at inclusion and were analysed by the same physicians. Left
bundle branch block was defined as QRS duration .120 ms; QS or rS
in lead V1; broad R waves in leads I, aVL, V5, or V6; and absent q waves
in leads V5 and V6.
Right bundle branch block required QRS duration .120 ms; rsr, rsR,
rSR, or qR in leads V1 or V2; and occasionally, a wide R wave and wide
S waves in leads I, V5, and V6. Intraventricular conduction delay was
defined as QRS .120 ms without typical features of LBBB or RBBB.
Device implantation procedure
Cardiac resynchronization therapy implantation was performed using a
transvenous approach according to current standards. During device im-
plantation, a coronary venous angiogram was performed to determine
the coronary sinus branch suitable for LV lead placement. Left ventricular
leads were implanted in the lateral position in 94 (75%) patients, in the
posterior position in 28 (23%) patients, and in the anterior position in
3 (2%) patients.
After LV lead positioning, LV pacing threshold, sensing parameters, and
LV impedance values were obtained and the pacing output was pro-
grammed to achieve an adequate pacing safety margins. In patients with
intraoperative LV lead dislodgement or phrenic nerve stimulation, repo-
sitioning and stabilization of the coronary sinus lead was performed using
coronary stent implantation, as previously described.10,11 The location of
the LV and RV leads was left to the physician’s discretion. The right ven-
tricular lead was recommended to be implanted in a septal position, and
the left ventricular lead was recommended to be implanted in a poster-
olateral or lateral position whenever there was a suitable coronary sinus
branch available. Left ventricular and RV lead positions were assessed by
chest X-rays in the right and left anterior oblique views and reported by
the implanting physician.
Right to left ventricular activation delay
measurement
The RV-LV activation delay measurements were performed after posi-
tioning the right and left ventricular leads, they were connected to an
electrophysiology system (Biotronik, Berlin, Germany). The right to left
interventricular sensed delay was measured by the time delay of the
peak activation in the right and left ventricular sensed signals. Right to
left ventricular activation delay was captured in milliseconds.
Follow-up in the study
Patients had a clinic visit every 6 months and at any meaningful clinical
event until the end of the study. Dates of death and HF episodes were
registered into the database.
Clinic visit included a physical examination, assessment of the NYHA
functional class, echocardiography, and a device interrogation. Heart
failure events were defined as symptoms and signs suggestive of HF
that prompted intravenous diuretic administration during an in-hospital
stay. All-cause mortality was assessed using the clinic follow-up data
and the National Health Fund Death Registry index.
Echocardiography
Echocardiography was performed according to current standards in a left
lateral position using Philips iE33 echocardiography system equipped
with an S5-1 transducer (Philips Healthcare, Best, The Netherlands).
What’s new?
† We evaluated the role of RV-LV activation delay (RV-LV AD)
during CRT implantation by baseline LBBB ECG morphology.
† There was greater reduction in mortality and heart failure
events with a longer RV-LV AD at device implantation and
LBBB.
† Patients with an LBBB ECG morphologyand a longer RV-LVAD
had significantly greater improvement in reverse remodelling,
and NT-proBNP.
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Image acqusition was performed according to current recommenda-
tions.12 Measurements were performed offline using the QLAB software
(Philips Healthcare). Left ventricular end-systolic and end-diastolic
volumes were measured, and EF was calculated by the biplane Simpson
method.12
Definitions and endpoints
Patients were categorized into two groups by the lower quartile of RV-LV
AD (86 ms) measured during CRT implantation: (i) those with RV-LV
AD, 86 ms and (ii) those with RV-LV AD ≥ 86 ms.
After assessing the role of RV-LV AD in the total patient cohort,
patients were further grouped by their baseline LBBB morphology, as
pre-specified. Right to left ventricular activation delay subgroups were
compared among LBBB patients only, and then among non-LBBB patients
only. Then, we combined patients with LBBB and RV-LV AD, 86 ms
with patients with non-LBBB (‘CRT non-responders’) and compared
them to patients with LBBB but RV-LVAD ≥ 86 ms (‘CRT responders’).
We also evaluated the changes in EF, in the distance walked during the
6-min walk test and in the level of NT-proBNP at 6-month follow-up in
CRT responders and CRT non-responders.
Furthermore, we assessed the changes in the biomarker NT-proBNP
and clinical outcome of HF/death and death by quartiles of RV-LVAD to
evaluate RV-LV AD as a continuous parameter.
The primary composite endpoint of the current studywasHFepisodes
requiring hospitalization or all-cause mortality during the follow-up. The
secondary endpoint was death from any cause.
Statistical analysis
The statistical analysis was performed using the Graph Pad Prism 5.0
software (Graph Pad Inc., CA, USA) and the SPSS software (IBM, NY,
USA). Continuous variables with a normal distribution are presented
as mean+ standard deviation, while parameters without a normal distri-
bution are shown as median and interquartile range (IQR). Categorical
variables are expressed as frequencies and percentages. Unpaired
t-tests were used for comparisons of normally distributed continuous
variables while not normally distributed variables were compared using
the Mann–Whitney test. For categorical variables, Fisher’s exact tests
were performed to assess the differences between the groups.
Time-to-event data were presented by Kaplan–Meier survival curves
using the log-rank test. Cox proportional hazards model was used to de-
termine independent predictors of all-cause death at 3 years after adjust-
ment for relevant clinical covariates. Hazard ratios (HRs) with a 95%
confidence interval (95% CI) were determined for clinical endpoints.
All statistical tests were two-sided, a P-value of,0.05 was considered
statistically significant. The statistical analysis was performed by the first
author of the paper, Annamaria Kosztin.
Results
Baseline clinical characteristics
Between September 2009 and December 2010, 125 patients were
enrolled in the study, 73 patients (58%) received a CRT with defibril-
lator (CRT-D), while 52 patients (42%) were implanted with a CRT
with pacemaker. The mean age of the study participants was
67.0+8.6 years, the mean EF was 28.2+6.5%. The majority
of the patients (71%) was in NYHA functional class III, 62% of them
had LBBB and 60% had ischaemic cardiomyopathy. The RV-LV AD
measurements were ranged between 40 and 175 ms, the mean
value was 106.10+ 29.98 ms in the entire patient cohort, in the
LBBB group 109.80+ 30.31 ms, in the non-LBBB group 100.0+
28.72 ms (P ¼ 0.07).
Baseline clinical characteristics of the patients with an RV-LV AD
≤86 and .86 ms (lower quartile) are listed in Table 1. Notably,
there were no major differences among patients with a shorter or
longer RV-LV AD in clinical or echocardiographic parameters.
After we further dichotomized the patient cohort by LBBB morph-
ology, we assessed the baseline clinical characteristics in patients
with LBBB and RV-LV AD ≥ 86 ms and compared with the group
of remaining patients such as LBBB and RV-LV AD , 86 ms and
patients with non-LBBB together (Table 2).
Right to left ventricular activation delay
and functional outcome 6 months after
cardiac resynchronization therapy
implantation
At 6-month follow-up, 33 (55%) patients with RV-LV AD ≥ 86 ms
and LBBB performed their 6-min walk test over 300 m, compared
with 23 of those patients (35%) with RV-LV AD , 86 ms or with a
non-LBBB (55 vs. 35%; P ¼ 0.01) (Table 3).
In patients with RV-LV AD ≥ 86 ms and LBBB, better laboratory
parameters were observed at 6 months after CRT implantation
with an NT-proBNP median value of 1216 (IQR: 326.9/2630) vs.
1887 (IQR: 1140/3300); P ¼ 0.03, a creatinine value of 96.3+56.6
vs. 122.1+46.9; P ¼ 0.01 and a blood urea nitrogen value of
7.6+ 4.7 vs. 10.9+5.6; P ¼ 0.001, when compared with non-
LBBB patients or to those with LBBB and RV-LV AD , 86 ms
(Table 3). Patients with RV-LV AD ≥ 86 ms and LBBB showed the
greatest improvement in left ventricular EF (28.0+ 7.1–36.3+
12.3; P, 0.001) 6 months after CRT implantation.
Right to left ventricular activation delay
and clinical outcome in the total patient
cohort
During the median follow-up of 2.2 years, 44 (35%) patients had HF
events or death, and 36 (29%) patients died. Sixteen (53%) patients
had HF or death with RV-LV AD, 86 ms, and 28 (29%) with
RV-LV AD ≥ 86 ms, while 11 (37%) patients died with RV-LV
AD , 86 ms, and 25 patients (26%) with RV-LV AD ≥ 86 ms.
Patients with RV-LV AD ≥ 86 ms had significantly lower cumula-
tive probability of HF/death when compared with those with
RV-LV AD, 86 ms (P ¼ 0.004) (Figure 1A). The cumulative prob-
ability of all-cause mortality was significantly lower in patients with
a longer activation delay (RV-LV AD ≥ 86 ms) compared with
thosewith shorterdelay (RV-LVAD, 86 ms, P ¼ 0.003) (Figure 1B).
Multivariate Cox-regression analysis confirmed the independent
role of RV-LV AD first as a continuous parameter (Table 4) and
then by 86 ms (Table 5) in predicting HF or death or all-cause mortal-
ity in the total patient population after adjustment for relevant clinical
covariates, namely for LBBBECG morphology, HFaetiologyand age at
enrolment. Patients with RV-LV AD ≥ 86 ms had a 56% significantly
lower risk of HF or death (HR: 0.44; 95% CI: 0.23–0.82; P ¼ 0.001)
and a 52% lower risk of all-cause mortality (HR: 0.48; 95% CI: 0.23–
1.00; P ¼ 0.05), compared with those with a shorter RV-LV activation
delay at CRT implantation (Table 5).
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Right to left ventricular activation delay
and clinical outcome by left bundle branch
block ECG pattern
The findings were even more pronounced in patients with an
LBBB ECG pattern. Patients with an LBBB and an RV-LV AD ≥
86 ms at implantation had a significantly lower cumulative prob-
ability of HF/death when compared with those with shorter ac-
tivation delay (RV-LV AD , 86 ms) and to those patients with
non-LBBB (P, 0.001) (Figure 2A). This difference was translated
into a 77% reduction in the risk of HF or death (HR: 0.23; 95%
CI: 0.11–0.49; P, 0.001), after adjustment for relevant clinical
covariates.
Furthermore, there was a significantly lower cumulative probabil-
ity of all-cause mortality in LBBB patients with a longer RV-LV
activation delay at implantation (RV-LV AD ≥ 86 ms), compared
with those with shorter activation delay (RV-LV AD, 86 ms)
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Table 1 Baseline clinical characteristics of CRT patients by RV-LV AD of 86 ms at device implantation
RV-LV AD ≥ 86 ms (n5 95) RV-LV AD < 86 ms (n 5 30) P-Value
Age in years (mean+ SD) 67.1+8.3 66.5+9.7 0.73
Female gender, n (%) 18 (19%) 6 (20%) 1.00
CRT-D, n (%) 53 (56%) 20 (67%) 0.39
RV-LV AD (ms; mean+ SD) 117.67+23.85 69.47+13.19 NA
Baseline medical history
Ischaemic aetiology, n (%) 56 (60%) 19 (63%) 0.25
Hypertension, n (%) 65 (70%) 22 (73%) 0.65
Diabetes mellitus, n (%) 31 (32%) 6 (20%) 0.25
Secondary prevention, n (%) 5 (4%) 5 (17%) 0.06
Prior myocardial infarction, n (%) 31 (32%) 14 (47%) 0.19
CABG, n (%) 17 (18%) 7 (23%) 0.60
Baseline clinical assessment
Sinus rhythm at enrolment, n (%) 64 (67%) 18 (60%) 0.51
QRS at baseline (ms, mean+ SD) 166.4+27.7 170.0+33.9 0.57
LBBB ECG morphology, n (%) 60 (63%) 18 (60%) 0.23
RBBB ECG morphology, n (%) 0 (0%) 2 (7%) 0.06
IVCD ECG morphology, n (%) 35 (37%) 10 (33%) 0.83
NYHA II, n (%) 16 (17%) 2 (6%) 0.24
NYHA III, n (%) 69 (73%) 23 (77%) 0.81
NYHA IVa, n (%) 10 (10%) 5 (17%) 0.35
Six-min walk test (m, mean+ SD) 307.4+128.8 268.1+128.6 0.22
Systolic blood pressure (mmHg, mean+ SD) 119.9+17.5 122.5+20.8 0.52
Diastolic blood pressure (mmHg, mean+ SD) 74.4+9.3 77.7+12.0 0.12
Heart rate at baseline (b.p.m., mean+ SD) 75.8+46.4 73.7+11.3 0.59
Baseline drug treatment
Beta blocker, n (%) 86 (91%) 24 (83%) 0.19
ACE inhibitor or ARB, n (%) 91 (96%) 27 (93%) 0.36
Spironolactone, n (%) 69 (74%) 18 (62%) 0.25
Loop diuretics, n (%) 77 (82%) 23 (80%) 0.61
Laboratory parameters
NT-proBNP (ng/mL; med, IQR) 2608.0 (1596/4945) 2815.0 (1232/4732) 0.88
Creatinine (mmol/L; med, IQR) 106.8+34.8 118.0+41.6 0.20
BUN (mmol/L; mean+ SD) 9.2+1.4 10.7+7.0 0.18
Echocardiography parameters
LVEF (%, mean+ SD) 28.5+5.5 28.1+6.9 0.82
LV end-diastolic volume (mL, mean+ SD) 249.6+49.3 253.4+82.7 0.86
LVESV (mL, mean+ SD) 181.4+50.4 184.0+67.4 0.85
RV-LVAD, right to left ventricular activation delay; CABG, coronary artery bypass graft; VF, ventricular fibrillation; LBBB, left bundle branch block; RBBB, right bundle branch block;
IVCD, intraventricular conduction delay; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LV, left ventricular; LVEF, left ventricular ejection fraction;
LVESV, left ventricular end-systolic volume; BUN, blood urea nitrogen.
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and to those patients with non-LBBB (P ¼ 0.01) (Figure 2B). This
translated into a 65% risk reduction in all-cause mortality in the multi-
variate models (HR: 0.35; 95% CI: 0.16–0.75; P ¼ 0.007) (Table 5).
In patientswith non-LBBB, therewas no significant difference in HF
or death or in all-cause mortality by RV-LV AD groups measured at
CRT implantation (HF/death HR ¼ 0.63; 95% CI: 0.26–1.49; P ¼
0.29, death HR ¼ 0.43; 95% CI: 0.15–1.20; P ¼ 0.11) (Table 5).
Clinical outcome by right to left
ventricular activation delay after
normalization to QRS
Our analyses were extended by RV-LVAD to QRS duration (RV-LV
AD/QRS), while in a recent publication its percentage value was
considered as feasible parameter with higher diagnostic value in
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Table 2 Baseline clinical characteristics of CRT patients by RV-LV AD of 86 ms and LBBB morphology
RV-LV AD ≥ 86 ms
LBBB patients (n 5 60)
RV-LV AD < 86 ms LBBB and
non-LBBB patients (n5 65)
P-Value
Age in years (mean+ SD) 67.5+7.9 66.3+9.6 0.49
Female gender, n (%) 16 (27%) 8 (12%) 0.07
CRT-D, n (%) 32 (53%) 41 (63%) 0.28
RV-LV AD (ms; mean+ SD) 121.30+23.56 92.05+28.50 NA
Baseline medical history
Ischaemic aetiology, n (%) 30 (50%) 45 (69%) 0.04*
Hypertension, n (%) 40 (67%) 47 (72%) 0.56
Diabetes mellitus, n (%) 16 (27%) 21 (32%) 0.23
Secondary prevention, n (%) 2 (3%) 8 (12%) 0.10
Prior myocardial infarction, n (%) 17 (28%) 28 (43%) 0.10
CABG, n (%) 7 (12%) 17 (26%) 0.04*
Baseline clinical assessment
Sinus rhythm at enrolment, n (%) 49 (82%) 33 (51%) 0.001***
QRS at baseline (ms, mean+ SD) 167.3+24.5 167.2+33.3 0.98
LBBB ECG morphology, n (%) N/A 18 (28%) N/A
RBBB ECG morphology, n (%) N/A 2 (3%) N/A
IVCD ECG morphology, n (%) N/A 45 (69%) N/A
NYHA II, n (%) 9 (15%) 6 (9%) 0.41
NYHA III, n (%) 46 (77%) 44 (68%) 0.32
NYHA IVa, n (%) 5 (8%) 15 (23%) 0.01*
Six-min walk test (m, mean+ SD) 316.0+132.6 282.9+125.2 0.22
Systolic blood pressure (mmHg, mean+ SD) 119.8+18.9 121.1+17.8 0.70
Diastolic blood pressure (mmHg, mean+ SD) 74.5+9.4 75.7+10.5 0.54
Heart rate at baseline (b.p.m., mean+ SD) 76.8+13.8 77.0+20.8 0.97
Baseline drug treatment
Beta blocker, n (%) 54 (90%) 56 (88%) 0.59
ACE inhibitor or ARB, n (%) 58 (97%) 60 (94%) 0.44
Spironolactone, n (%) 42 (70%) 45 (70%) 1.00
Loop diuretics, n (%) 45 (75%) 55 (86%) 0.19
Laboratory parameters
NT-proBNP (ng/mL; med, IQR) 2608 (1063/4664) 2612.0 (1739/5049) 0.21
Creatinine (mmol/L; med, IQR) 101.9+45.0 116.1+36.8 0.06
BUN (mmol/L; mean+ SD) 9.0+4.7 10.1+5.4 0.21
Echocardiography parameters
LVEF (%, mean+ SD) 27.6+7.6 28.0+6.6 0.77
LV end-diastolic volume (mL, mean+ SD) 263.1+86.1 233.5+69.1 0.08
LVESV (mL, mean+ SD) 194.5+70.0 168.3+56.4 0.04*
RV-LVAD, right to left ventricular activation delay; CABG, coronary artery bypass graft; VF, ventricular fibrillation; LBBB, left bundle branch block; RBBB, right bundle branch block;
IVCD, intraventricular conduction delay; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LV, left ventricular; LVEF, left ventricular ejection fraction;
LVESV, left ventricular end-systolic volume; BUN, blood urea nitrogen.
N/A, not applicable due to the definition of the groups.
*P, 0.05.
***P, 0.001.
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predicting the clinical response and purely evaluates the adequacy of
LV lead placement for effective CRT.13
The univariate model showed RV-LVAD/QRS is also an independ-
ent factor of the primary endpoint of HF and death in LBBB patients
(HR: 0.08; 95% CI: 0.01–1.02; P ¼ 0.05). These results werealso con-
firmed by multivariate Cox-regression analysis: by using the optimal
cut-off value of percentage RV-LV AD/QRS which was 64%. Those
who have higher RV-LV AD to QRS ≥ 64% have lower risk for HF
events or death in the total patient cohort (HR: 0.43; 95% CI:
0.23–0.81; P ¼ 0.10) and in LBBB patients as well (HR: 0.28; 95%
CI: 0.10–0.80; P ¼ 0.017). The lowest cumulative probability of
HF/death was observed in patients with higher percentage of
RV-LV AD/QRS and LBBB morphology (HR: 0.21; 95% CI: 0.08–
0.54; P ¼ 0.001) compared with non-LBBB or low RV-LV AD/QRS
patients. In multivariate analyses, models were adjusted for age and
ischaemic aetiology (data not shown).
Functional outcome, NT-proBNP 6 months
after cardiac resynchronization therapy
implantation and clinical outcome by right
to left ventricular activation delay quartiles
To further assess the effects of RV-LVAD as a continuous parameter
on NT-proBNP and clinical outcome of HF/death, we evaluated the
changes in NT-proBNPat6 monthsbyRV-LVADquartiles alongwith
the incidence of HF/death. We found a linear increase in the amount
of reduction in NT-proBNP 6 months after CRT towards the longer
RV-LV AD quartile subgroups. In parallel with the improvement
in NT-proBNP, there was a linear decrease in the incidence of HF/
death (Figure 3).
Besides the beneficial changes in NT-proBNP, the better clinical
outcome was reflected in the improvement of renal function between
patients with longer RV-LV AD and LBBB morphology compared
with those, who had shorter activation delay or non-LBBB morphology
(Table 3). Significant differences were found in changes in serum creatin-
ine after6 months (96.3+56.6 vs. 122.1+ 46.9 mmol/L;P¼ 0.01), and
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Table 3 Clinical parameters at 6 months after CRT implantation
RV-LV AD ≥ 86 ms
LBBB patients (n 5 60)
RV-LV AD < 86 ms LBBB and
non-LBBB patients (n 5 65)
P-Value
Clinical assessment
Six-min walk test .300 m, n (%) 33 (55%) 23 (35%) 0.03*
Systolic blood pressure (mmHg, mean+ SD) 127.4+19.3 122.2+24.8 0.27
Diastolic blood pressure (mmHg, mean+ SD) 77.2+9.4 73.2+12.0 0.08
Laboratory parameters
NT-proBNP (ng/mL; med, IQR) 1216 (326.9/2630) 1887 (1140/3300) 0.03*
Creatinine (mmol/L; med, IQR) 96.3+56.6 122.1+46.9 0.01*
Blood urea nitrogen (mmol/L; mean+ SD) 7.6+4.7 10.9+5.4 0.001**
*P, 0.05.
**P, 0.01.
Figure 1 Kaplan–Meier cumulative probability of HF/death (A)
and death (B) by RV-LV AD.
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more pronounced in BUN (7.6+4.7 vs. 10.9+ 5.4 mmol/L;
P ¼ 0.001).
Discussion
The main findings of our study are that LBBB patients with an RV-LV
activation delay of ≥86 ms have a significantly lower risk of HF or
death and lower risk of all-cause mortality compared with those
with non-LBBB ECG morphology combined with LBBB and RV-LV
AD, 86 ms. In non-LBBB patients, RV-LV AD was not predictive
of clinical outcome. Furthermore, we found that RV-LVAD has an in-
dependent role in predicting improvement in left ventricular EF,
NT-proBNP, and functional outcome in LBBB patients undergoing
CRT implantation.
In this study,weused86 msasacut-off value forRV-LVAD, the lower
quartile of RV-LVAD to predict the primary composite endpoint, which
was pre-specified in our analysis. D’onofrio et al.9,13 published similar
results in 301 patients who underwent CRT implantation and had
LBBB morphology. In this article, ROC curves showed 80 ms as the
optimal cut-off value of RV-LV AD and 65% of its normalization to
QRS. Those patients who had greater RV-LV AD than 80 ms or
RV-LVAD to QRS than 65% had significantly better outcome in echo-
cardiographic reverse remodelling, which was defined as .15% end-
systolic volume change. Their results are in line with our findings, the
normalization of AD to QRS is also a feasible parameter in selecting
patients who might benefit from CRT implantation. Those who have
higher RV-LV AD to QRS and LBBB morphology have the lowest risk
for HF events or death. The assessment of these parameters has
higher importance in the subgroup of patients who have narrower QRS.
In another study by Kristiansen et al.,8 they used an RV-LV interlead
sensed electrical delay of ≥85 ms and showed differences in echo-
cardiographic response and in clinical outcome. However, none of
these studies looked specifically at subgroups of LBBB and non-
LBBB patients.
Other studies used a different approach of evaluating successful
resynchronization with CRT. Gold et al.14 were focusing on the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Univariate models to evaluate the clinical outcome of CRT patients by continuous value of RV-LV AD and LBBB
ECG morphology at baseline
Hazard ratio 95% confidence interval P-Value
Primary endpoint: HF event or death
RV-LV AD in all patients (125 patients) 0.98 0.97–0.99 0.015*
RV-LV AD in LBBB (78 patients) 0.98 0.96–0.99 0.029*
RV-LV AD in non-LBBB (47 patients) 0.99 0.97–1.00 0.36
Secondary endpoint: all-cause mortality
RV-LV AD in all patients (125 patients) 0.98 0.97–0.99 0.0001***
RV-LV AD in LBBB (78 patients) 0.97 0.96–0.99 0.03
RV-LV AD in non-LBBB (47 patients) 0.12 0.97–1.00 0.98
*P, 0.05.
***P, 0.01.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Multivariate models to evaluate the clinical outcome of CRT patients by RV-LV AD and LBBB ECG morphology
at baseline
Hazard ratio 95% confidence interval P-Value
Primary endpoint: HF event or death
RV-LV AD ≥ 86 ms vs. ,86 ms in all patients (95 vs. 30 patients) 0.44 0.23–0.82 0.001**
RV-LV AD ≥ 86 ms vs. ,86 ms in LBBB (60 vs. 18 patients) 0.18 0.63–0.52 0.001**
RV-LV AD ≥ 86 ms vs. ,86 ms in non-LBBB (35 vs. 12 patients) 0.63 0.26–1.49 0.29
RV-LV AD ≥ 86 ms in LBBB vs. Others (60 vs. 65 patients) 0.23 0.11–0.49 ,0.001*
Secondary endpoint: all-cause mortality
RV-LV AD ≥ 86 ms vs. ,86 ms in all patients (95 vs. 30 patients) 0.48 0.23–1.00 0.05*
RV-LV AD ≥ 86 ms vs. ,86 ms in LBBB (60 vs. 18 patients) 0.37 0.12–1.18 0.09
RV-LV AD ≥ 86 ms vs. ,86 ms in non-LBBB (35 vs. 12 patients) 0.43 0.15–1.20 0.11**
RV-LV AD ≥ 86 ms in LBBB vs. Others (60 vs. 65 patients) 0.35 0.16–0.75 0.007*
Models are adjusted for age at enrolment, ischaemic aetiology of heart failure, and for LBBB ECG pattern in the model on the total patient population.
*P, 0.05.
**P, 0.01.
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association of clinical outcome and ventricular electrical delay mea-
sured by Q-LV in 426 patients with advanced HF, measuring LV
lead activation time from the beginning of the QRS. Similarly to our
results they found significant differences in functional parameters
such as ESV reduction and in the quality-of-life 6 months after CRT
implantation in those patients who had a greater Q-LV time than
the median of 95 ms.
Right to left ventricular activation delay, the parameter used in our
study is however a more comprehensive measurement providing in-
formation not only about the LV lead, but also about the RV lead pos-
ition. Several studies have indicated that the location of the right
ventricular lead plays a role in the clinical outcome of CRT patients.15
Furthermore, RV-LV activation delay may reflect slow conduction,
as it is frequently seen in patients with ischaemic heart disease and
extensive scarring of the posterior or lateral wall. However, we did
not have data available on this in our cohort.
At the same time, it seems that RV-LVAD may point to significant
electrical dyssynchrony that could be better surrogate marker for
CRT benefit than mechanical dyssynchrony. A recent editorial sug-
gests LBBB as an electrical disease, and CRT as a potent therapy
for this electrical disease.16 Therefore, it is sensible that patients
with non-LBBB did not derive a significant benefit in our study,
despite short or long RV-LV AD at implantation. The disease
process may be more complex in patients with non-LBBB and
needs further investigation.
This study is in line with several previous studies5,17,18 suggesting
that best response to CRT is achieved in patients with a ‘left bundle
branch block cardiomyopathy’ with optimal positioning of the left
Figure 2 Kaplan–Meier cumulative probability of HF/death (A) and death (B) by RV-LV AD and LBBB ECG morphology.
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ventricular lead. However to our knowledge, this is one of the first
studies evaluating the effect of RV-LV activation delay in patients
undergoing CRT by their baseline LBBB ECG pattern. Some of the
previous studies adjusted the multivariate models for LBBB, but
there were no pre-specified subgroup analysis performed in patients
with a baseline LBBB or non-LBBB.
Moreover, in the current study the beneficial outcome was
reflected in the decrease of prerenal dysfunction, independently of
the baseline renal function values. In patients with longer RV-LV
AD and LBBB morphology, serum creatinine and BUN values were
significantly lower than in those with shorter RV-LV AD or non-
LBBB ECG morphology.
Several trials assessed the independent risk factor of impaired
renal function for mortality and morbidity in chronic HF.19,20 The
markers of prerenal dysfunction were also discussed in mildly symp-
tomatic21 and in advanced HF22 after resynchronization. However,
the association of RV-LVAD and the latter changes in renal function
have not been directly investigated.
Our study has certain limitations, RV-LV AD may have been influ-
enced by baseline QRS duration and by the suitable coronary sinus
side branches. However, as a sensitivity analysis, we adjusted our
models for QRS duration and our results were similar. Furthermore,
suitable vein distribution for LV lead implantation is a known bias
for all CRT studies and therefore needs to be acknowledged.
Alternatively, minimal invasive techniques, e.g. mini-thoracotomy
LV lead implantation23 or transseptal LV endocardial pacing could
be used to further maximize RV-LV AD and optimize CRT
outcome. However, such methods have not become widely used
in the past due to the relative invasive nature of the procedure.
Furthermore we included only 125 patients in our study, and a
small proportion of them had non-LBBB. Therefore, we may have a
limited power to assess differences among non-LBBB patients by
RV-LV AD. Further studies are warranted to evaluate the value of
RV-LV AD in non-LBBB patients. Besides we adjusted our models
for potential confounders, however, other unmeasured confounders
may have influenced our results.
Conclusions
In conclusion, a longer RV-LV activation delay at CRT implantation was
associated with improvement in EF, NT-proBNP, and with better
HF-free survival and overall survival in patients with LBBB, but not in
those with a shorter RV-LV activation delay, or in those with a
non-LBBB.SimpleassessmentofRV-LVactivationdelayduringCRT im-
plantation might be a useful method to improve outcomes after CRT.
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